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Abstract 
Coagulation is a critical event in innate immunity designed to prevent bacterial invasion 
and blood loss, that occurs on the external membrane surface of activated platelets and 
leukocytes. Herein, we show using lipidomic, genetic, biochemical and mathematical 
modeling approaches that enzymatically-oxidized phospholipids (eoxPL) from leukocyte 
or platelet lipoxygenases (LOX) are required for normal clotting, by promoting 
coagulation factor activities in a calcium and phosphatidylserine (PS)-dependent manner.  
In wild type mice, hydroxyeicosatetraenoic acid-phospholipids (HETE-PLs) enhanced 
coagulation, and restored normal hemostasis in p12- or 12/15-LOX deficient animals, 
which failed to generate normal thrombus in vivo.  Murine platelets generated 22 diverse 
eoxPL species, that were missing in p12-LOX deficiency. Humans with the thrombotic 
disorder antiphospholipid syndrome (APS) had significantly elevated HETE-PLs in 
platelets and leukocytes, and higher HETE-PL immunoreactivity. HETE-PLs also 
enhanced membrane binding of β2GPI, a process considered central to developing an 
immune response in APS.  Correlation network analysis of 47 platelet eoxPL species in 
APS and control platelets identified their enzymatic origin and revealed a complex 
network of regulation, with 31 p12-LOX-derived eoxPL significantly elevated in thrombotic 
disease.  In summary, circulating blood cells generate networks of eoxPL, including 
HETE-PLs that change membrane properties to enhance clotting during innate immunity 
and bleeding challenge, and are significantly elevated in the thrombotic disease, APS. 
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Introduction 
Blood clotting is an essential first step in innate immunity, required to prevent bacterial 
invasion and ensure effective hemostasis following injury. Excess clotting in the 
vasculature underlies vascular inflammatory conditions including myocardial infarction, 
stroke, pulmonary embolism and deep vein thrombosis, while impaired coagulation 
contributes to excessive blood loss during surgery and childbirth, the commonest cause 
of mortality during childbirth. Thus, a fuller understanding of the molecular processes 
underlying coagulation/hemostasis could drive development of effective new treatments 
and help inform prevention strategies for several major human disorders.   
Hemostasis depends on the coagulation cascade, a series of serine proteases 
and co-factors in plasma, initiated by tissue factor (TF).  For clotting to occur, amino-
phospholipid (aPL) externalization on the platelet surface following activation is required.  
Here, scramblase leads to phosphatidylethanolamine (PE) and –serine (PS) 
translocation, providing a negative charge to facilitate calcium binding and factor 
association (1,2). aPL externalization alone is not sufficient for full physiological 
coagulation since the rare disorder Scott Syndrome presents with an inability to 
externalize PS/PE, but only a relatively minor bleeding phenotype, unless under 
significant haemostatic challenge (3). This suggests additional PLs are involved.  
Activated platelets and leukocytes rapidly generate oxidized PEs and 
phosphatidylcholines (PCs) via lipoxygenases (LOX), termed hydroxyeicosatetraenoic 
acid-phospholipids (HETE-PL) that reside at or within the plasma membrane (4-10). 
HETE-PL positional isomers are exclusively cell type and LOX isoform dependent, thus 
5-, 12- and 15-HETE-PLs are generated by human neutrophils, platelets or monocytes 
respectively.  However, in mice, where leukocytes express a 12/15-LOX homolog, 12-
	 5	
HETE-PLs are instead formed (7).  We recently identified COX-1 derived enzymatically-
oxidized PL (eoxPL) generated by platelets, containing either PGE2, PGD2 or dioxolane 
A3 (DXA3), and then, using global lipidomics mass spectrometry mapped out 103 eoxPL 
molecular species in thrombin-activated human platelets (11-13). This indicated that 
eoxPL generation is a far broader phenomenon than previously thought, although the 
enzymatic origin of most members of this large group remained unknown.  
Antiphospholipid syndrome (APS) is an acquired prothrombotic disorder caused 
by a diverse family of circulating “antiphospholipid” antibodies. These can be directed 
against phospholipids including PE or cardiolipin, β2GPI or other PL-binding proteins. In 
APS, pathogenic antibodies contribute to thrombotic episodes or pregnancy 
complications (14-16). An interaction between β2GPI and negatively-charged 
phospholipids on the surface of cells is thought to be required for disease development 
(15,16). The phospholipids that provide optimal binding of β2GPI to membranes are 
unknown. Given that eoxPL are generated at significant rates by isolated blood cells and 
platelets, contain electronegative hydroxyl groups on their fatty acids, and remain cell-
associated after their formation, we decided to explore their generation in APS. 
Herein, we use biochemical, genetic, clinical, mathematical and lipidomic 
approaches to reveal the pro-coagulant mechanisms of endogenously generated LOX-
derived eoxPL from platelets and leukocytes in vitro and in vivo and show they increase 
β2GPI binding to membranes.  We undertook correlation network analysis of the 47 most 
abundant eoxPL in platelets from a human APS cohort, revealing several levels of 
enzymatic regulation, and show their elevated generation and enhanced immune 
recognition in disease.  Overall, our studies provide a novel paradigm for hemostasis 
where the generation of multiple eoxPL by platelets and leukocytes is required for normal 
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coagulation to occur, and is chronically elevated during human venous thrombotic 
disease associated with APS.   
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Results 
HETE-PL isomers enhance thrombin generation in platelet poor plasma.  
Coagulation requires multiple enzyme/cofactor complexes that ultimately generate 
thrombin (factor IIa, FIIa), specifically TF/FVIIa, FIXa/FVIIIa (intrinsic tenase) and 
FXa/FVa (prothrombinase), and takes place on phospholipid membranes (17-19). To 
support this, plasma membranes externalize aminophospholipids, PS and PE 
(17,18,20,21). It has been shown that PS is required to support coagulation whilst PE 
enhances PS activity (1,2,22). PS and PE bind coagulation factors II, VII, IX and X, in a 
calcium-dependent manner, through their gamma carboxylated glutamic acid (Gla) 
domains (17,23) and FVIII and FV through C domains (24,25). To examine the effects of 
HETE-PLs on coagulation, the lipids were incorporated into TF-containing liposomes and 
added to pooled plasma.  Increasing concentrations of 5-,12- or 15-HETE-PE or –PC all 
enhanced coagulation in a concentration-dependent manner (Fig. 1 A to F).  
 
HETE-PL enhance the prothrombotic action of PS in platelet poor plasma.  
The accepted model of coagulation is that PS supports the prothrombinase and intrinsic 
tenase complexes, while PE enhances the effect of PS. PC is thought to have no role in 
supporting coagulation (2). To determine the pro-coagulant mechanisms of HETE-PLs, 
thrombin generation was measured at varying PS concentrations. In the absence of PS, 
native PE supported low thrombin generation, which doubled on substitution with 15-
HETE-PE (Fig. 1, G and H). Gradually increasing PS led to dose dependent elevations in 
thrombin generation, which were similarly elevated by HETE-PE (Fig. 1, G and H).  In 
contrast, PC (either native or HETE-PC) was unable to support thrombin generation 
without PE/PS (Fig. 1, I and J). Here, gradually increasing PS led to a dose dependent 
increase in thrombin generation. However, in contrast to HETE-PE, the enhancing effect 
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of HETE-PC was greater at higher PS concentrations (Fig. 1J).   Specifically at 1 % or 30 
% PS, HETE-PC increased thrombin generation approximately 20%, or 175%, 
respectively.  This indicates a synergistic effect of HETE-PC with PS.   The data indicate 
a mechanism by which HETE-PLs enhance PS dependent coagulation, similar to native 
PE, but far more potently.  The pro-coagulant action of HETE-PC is highlighted since PC 
was previously assumed not to support PS in coagulation reactions (2,26).  
 
HETE-PLs stimulate thrombin generation in a simplified, purified cascade.  Thrombin 
generation in platelet poor plasma (PPP) is also influenced by anticoagulant factors. To 
further explore mechanisms, experiments were performed in a synthetic system using 
purified proteins at physiological concentrations of FII (1.4 µmol/L), FV (26 nmol/L), FVII 
(10 nmol/L), FVIII (300 pmol/L), FIX (80 nmol/L) and FX (136 nmol/L) without inhibitors of 
coagulation. Thrombin generation was triggered by TF-containing liposomes as for 
plasma experiments above. 15-, 12- and 5-HETE-PE and –PCs all significantly elevated 
thrombin generation (Fig. 1, K to M).  
 
Molecular modeling shows bending of HETE with localization of –OH at the membrane 
surface, and association with calcium molecules.   A molecular dynamics simulation was 
performed to understand how the hydroxyl group of 12-HETE-PC would behave within 
the membrane. An available pre-equilibrated DOPC membrane with 128 molecules was 
modified to give a composition of 5% SAPS, 5 % SAPC, 30% SAPE, 55% DOPC, 5% 12-
HETE-PC. This includes 3 molecules of PS and HETE-PC per leaflet.  On one side, 
HETE-PCs were placed with HETEs buried in the membrane (in the yellow hydrophobic 
compartment), while on the other they were placed in a bent up configuration, with the –
OH close to the polar membrane surface.  During the 300 ns simulation, the system 
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remained stable. The polar membrane surface is shown in blue, with uncharged PC 
headgroups in grey). Notably, during the simulation all of the HETE-PCs with HETEs 
pointing downwards changed conformation to place the -OH group at the charged 
surface of the membrane (blue), while those already in that configuration remained stable 
(Fig. 2, A to D). In this position the –OH could establish a hydrogen bond with the nearby 
lipid phosphates, and in some cases, with the carboxylic acid group of neighboring PS 
(Fig. 2D). The OH- also appeared to interact with calcium ions (Fig. 2, B and C). As 
expected, calcium ions (red) strongly interact with PS headgroups during the whole 
duration of the simulation (Fig. 2, C and D).  As a result, both the HETE-OH and the PS 
carboxylic acid favor a close interaction between the surface of the membrane and the 
calcium ions of the water phase.  We also visualized the bilayer from above (blue: 
positive charge, brown: negative charge) and note that the –OH is visible for all 3 HETE-
PCs (red) facilitating formation of a more negatively charged space, pushing headgroups 
apart and making space for calcium to bind, in some cases near PS (pink) (Fig. 2E).  A 
movie showing 12-HETE-PC movement during the 300 ns simulation is provided as 
supplementary (lipid simulation.avi).  Viewing on a mac is best done with VLC Media 
Player (http://www.videolan.org/vlc/download-windows.en-GB.html).  In this, the HETE 
was originally placed aligned to other fatty acyl groups but around 100 ns, it moves up to 
orientate the –OH group near the polar region, and remains there, near calcium for the 
remainder of the simulation.  
 
HETE-PE increases calcium membrane binding.  To experimentally test for an interaction 
of calcium with HETE-PLs, we measured Fluo-FF fluorescence in the presence of 
liposomes, maintaining PC, PS and total PE concentrations, but gradually replacing PE 
with 12-HETE-PE up to 10 %.   In this assay, lipid-dependent lowering of Fluo-FF 
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fluorescence indicates elevated membrane calcium binding, which is then calculated as 
described in Methods.  In the presence of either 10 or 20 µM CaCl2, control liposomes 
bound 1 or 2.5 µM calcium, respectively.  This increased significantly and almost doubled 
at 3 - 10 % HETE-PE (Fig. 2F).  These data support our hypothesis that HETE-PLs 
facilitate calcium binding on the surface of membranes, to enhance PS-dependent 
clotting factor binding and activity.  
 
HETE-PLs enhance coagulation and promote hemostasis in vivo.  We next tested the 
ability of HETE-PLs to promote coagulation in vivo.  For this, liposomes containing two 
different concentrations of 12-HETE-PE or PC were injected intradermally into the tails of 
wild type mice, immediately proximal to a tail cut.  Control liposomes were without effect 
while either 78 or 19 ng HETE-PL (per injection) significantly inhibited bleeding, in some 
cases leading to total cessation (Fig. 3A).  Separately, liposomes were injected i.v. into 
wild type mice and thrombin-antithrombin complexes (TAT) were significantly elevated 
after 1 hr where liposomes contained 19 ng 12-HETE-PE (Fig. 3B).  These data indicate 
that HETE-PLs are pro-coagulant in healthy mice in vivo. Next, we measured eoxPL 
generation by murine platelets in vitro, from mice genetically lacking p12-LOX.  Washed 
platelets from wild type but not p12-LOX-/- mice generated multiple isomers of 12-HETE-
PE and –PC in response to thrombin activation (Fig. 3C, full data is shown in fig. S1).  
Both plasmalogen and acyl forms and also analogous eoxPL from 22:4, 22:5 and 22:6 
fatty acids were found, with all requiring p12-LOX (Fig. 3C). Time courses showed that 
HETE-PLs are already elevated at 5 min but continued to increase at least to 30 min post 
thrombin activation (Fig. 3D).  
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Genetic deficiency of p12-LOX or 12/15-LOX leads to a bleeding defect that can be 
corrected with HETE-PE administration. To test the involvement of p12-LOX in regulating 
coagulation in vivo, venous thrombosis was induced using FeCl2 as described in 
Methods.  In humans, venous thrombosis is predominantly associated with dysregulated 
activation of coagulation factors, whereas platelet activation is associated with arterial 
thrombosis.  In this model, significantly lower thrombus weight was observed in p12-LOX-
/- mice (Fig. 4, A and B).  Mice lacking either p12- or 12/15-LOX also showed a 
significantly increased tail bleeding time as well as elevated blood loss (Hb loss) (Fig. 4, 
C and D). We next tested whether administration of HETE-PLs restores hemostasis in 
vivo, in either p12- or 12/15-LOX-/- mice, by administering small doses immediately 
proximal to a tail cut.  Control liposomes contain 65% PC, 35% PE and 5% PS and may 
be expected to have partial pro-coagulant activities depending on dose. In either case, 
administration of 19 ng 12-HETE-PE in liposomes restored hemostasis back to wild type 
amounts, and in all cases was significantly more effective than control liposomes at 
reducing bleeding time (Fig. 4, C and D).  These data show that HETE-PLs are pro-
coagulant in vivo, and our findings using LOX deficient strains provides an explanation 
why their absence in either platelets or leukocytes causes a bleeding defect.  
 
Leukocyte and platelet HETE-PEs are elevated in APS.   To characterize HETE-PL 
generation in a human disease associated with venous thrombosis, HETE-PEs were 
quantified in isolated platelets and leukocytes from patients with antiphospholipid 
syndrome and healthy controls.  Basally, significantly elevated 5-HETE-PE (from 
neutrophils, monocytes, via 5-LOX) and 15-HETE-PE (from eosinophils, via 15-LOX) was 
detected in leukocytes from APS patients as compared to healthy volunteers (Fig. 5, A 
and B).  Following calcium ionophore activation, HETE-PEs increased in both groups to a 
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similar amount (Fig. 5, A and B). This indicates that leukocyte LOXs generate HETE-PEs 
basally in APS. The lack of difference following ionophore stimulation between HC and 
APS could imply that 15- and 5-LOX expression is similar in leukocytes from both groups 
although HETE-PL generation will also depend on AA availability and re-esterification 
rate into lysoPLs. APS platelets contained significantly more 12-HETE-PE than controls, 
both basally and following thrombin activation (Fig. 5C). Furthermore, APS platelet 
isolates tended to spontaneously aggregate during isolation. Specifically, no healthy 
subject platelets aggregated until thrombin challenged, while of the 12 APS isolates, 9 
appeared to at least slightly aggregate during the last washing step of platelet isolation, 
and of those, 7 generated a platelet “clot” that we removed and analyzed separately and 
show in Fig. 5 D. Our platelet isolation method is designed to minimize spontaneous 
activation.   Thus, platelets from APS patients are inherently more “poised” to activate.  
The detailed reasons are unknown, but it is an important unanswered phenomenon in 
APS pathophysiology.  12-HETE-PE in these spontaneously-aggregated platelets was 
similar to amounts in thrombin-activated APS platelets (Fig. 5, C and D). Increased 
platelet activation in vivo in APS was confirmed by measuring 11-thromboxane B2 
(TXB2), a urinary metabolite of thromboxane A2 formed by platelet COX-1 (Fig. 5E).  This 
is consistent with APS platelets circulating in a heightened activation state in vivo.  
 Next, we next analyzed leukocytes for platelet-derived 12-HETE-PEs and platelets 
for leukocyte-derived 5- and 15-HETE-PEs. 15- and 5-HETE-PEs were elevated basally 
in APS platelets (Fig. 5, F and G).  Unlike 12-HETE-PE, these did not significantly 
increase with thrombin, indicating they were not from platelets, but could represent 
microparticles from other cells attached to platelets. APS leukocytes had elevated 
platelet 12-HETE-PE compared to controls, that increased further on ionophore activation 
(Fig. 5H).  Thus, platelets or platelet-derived microparticles may be associated with APS 
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leukocytes during isolation and remain responsive to ionophore activation in vitro.  It is 
well known that platelet derived microparticles are elevated in APS, and we previously 
showed that 12-HETE-PE and –PC can be present in vesicles generated by thrombin-
activated platelets in vitro (9,27). 
Our patients were almost all taking anti-coagulant medication thus an influence of 
this on eoxPL cannot be excluded (Supplementary Table 1). Although samples sizes 
were small, gender, age and concurrent arterial thrombosis did not appear to influence 
eoxPL levels (fig. S2).   
 
APS patients have elevated plasma IgG directed against HETE-PEs. 
We sought to determine if HETE-PLs act as an antigen for antibodies in APS by 
measuring HETE-PE-specific IgG, compared with the unoxidized analog, 1-stearoyl-2-
arachidonyl-PE (SAPE).  APS serum had a significant elevation in IgG recognizing 5-, 
12- and 15-HETE-PEs (Fig. 6, A to C). IgG against SAPE was also increased, but this 
was not significant.  Total IgG was comparable between groups (Fig. 6D).  This suggests 
that chronic higher exposure to HETE-PEs leads to elevated immune recognition of these 
lipids in patients.   
 
HETE-PEs enhance APS-associated plasma protein binding to the cellular surface. 
β2GPI is a positively charged protein that binds to anionic PLs such as cardiolipin, 
resulting in a conformational change that exposes cryptic epitopes recognized by 
pathogenic disease-associated antibodies (15). This interaction is believed to result in 
downstream signaling with a net pro-coagulant effect.  Since HETE-PLs can enhance 
calcium binding (Fig. 2F), we tested whether they can also increase β2GPI interactions 
with the plasma membrane using PS/PC containing-liposomes. Binding of human purified 
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β2GPI was enhanced by cardiolipin, or on substitution of SAPE with 15-HETE-PE (Fig. 
6E). Also, 5- or 12-HETE-PE elevated cardiolipin-dependent β2GPI binding to the 
liposome in comparison to HETE-PEs or cardiolipin alone (Fig. 6F).  Thus, HETE-PEs 
enhance binding of β2GPI to membranes, a process required for the protein to become 
antigenic.   
 
Lipidomics defines the complexity of eoxPL enzymatic generation in human platelets 
including new control networks.   Recently we showed that over 100 eoxPL are acutely 
generated by thrombin-activated human platelets (11-13). The enzymatic origin of most 
of these lipids was not defined.  Here, the 47 most abundant were profiled in healthy 
control and APS platelets (both basally and after thrombin activation), to examine their 
behavior in the context of a thrombotic disease, and relative amounts are shown as a 
heatmap (Fig. 7A, full data including replicates is shown in fig. S3). In the heatmap, 
upregulation is denoted by red, and downregulation by blue. Deeper tones indicate 
greater differences, with comparisons made for individual lipids made across samples. 
Where origin is known, lipids were labeled as from either COX-1 (blue) or p12-LOX (red), 
based on either their absence in 12-LOX-/- mouse platelets, established herein, or for 
PGE2- or DXA3-PEs, a known sensitivity to aspirin (Fig. 3 D) (11,12). Clear clustering is 
seen with two prominent groups of related lipids visible based on COX-1 or p12-LOX. 
Several polyhydroxylated lipids grouped with COX-1 suggesting they may also originate 
from that pathway (green) while five mono-hydroxylipids (black) also grouped with p12-
LOX.  Notably, eoxPL clustered strongly based on the Sn2 fatty acid, with HDOHEs, 
HETEs and monohydroxy C22 lipids forming associated groups. From visual inspection, 
12-LOX derived lipids appear to upregulate stronger with thrombin than other lipids, and 
are higher in the APS vs HC groups.  
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Next, we plotted correlations between lipids (i.e. how each lipid behaves in relation 
to others individually) to further examine their behavior within the APS cohort (Fig. 
7B).  Here, lipids were sorted by decreasing correlation with 18:0a/12-HETE-PE, an 
abundant eoxPL generated by p12-LOX.  As for the heatmap, p12-LOX and COX-1-
derived lipids grouped together, with polyhydroxylated lipids again correlating closer with 
COX-1.  However, this visualization also revealed a family that correlated with 
16:0e/22:5(O)-PE (red arrows) (Fig. 7B).  Notably, almost all were acyl-PEs and PCs, 
with exclusively either 22:5 or 22:4 monoxygenated fatty acids at Sn2, and several are 
p12-LOX derived. This suggests that 12-LOX forms 22:4(O) or 22:5(O) PLs that 
regulated as a group. Along with the heatmap, this further supports the idea of differential 
behavior, based on the Sn2 oxidized fatty acid composition.  For both heatmap and 
correlation analyses, we normalized all lipids to the mean of the control unstimluated 
values.  In that way, we examined how each lipid behaves individually, relating to 
activation or health/disease.  There are major differences in abundance between 
individual lipids, e.g. HETE-containing PLs predominate while lipids from less abundant 
fatty acids, or with multiple oxygens are present in lower amounts (13). If data is not 
normalized, then correlations will be influenced by amounts rather than biological 
pathways. We also generated correlations where we separated out APS and HC 
datasets.  While these appear visually distinct, the same trends where 12-LOX derived 
lipids or COX-1/polyoxygenated lipids correlated in groups due to biological pathway was 
maintained (fig S4).   
We then characterized the 47 lipids using a network analysis (Cytoscape 3.2.1), 
where nodes represent individual lipids and degree (size) is determined by the number of 
links to others (Fig. 8A). Edge thickness represents the strength of correlation between 
individual nodes. Nodes with the highest degree cluster toward the center. The network 
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diagram illustrates that COX-1 and p12-LOX derived lipids behave as two separate 
groups, with only a small degree of relatedness between them.  The analysis further 
showed all remaining 20:4(3O) lipids locate with COX-1, suggesting them to be 
prostaglandin (PG)-containing PLs.  Four PEs correlated with p12-LOX, indicating this as 
their origin. When analyzed as a single group, the thirty one p12-LOX derived eoxPL 
were significantly elevated in APS platelets both basally and following thrombin 
stimulation, while for COX-1 derived eoxPL, a trend towards higher amounts in APS was 
noted (Fig. 8B). Last, a group of exclusively plasmalogen mono or dioxygenated-PEs 
from 22:5 or 20:4 behaved as a separate family, suggesting a different enzymatic origin 
to either COX-1 or p12-LOX (Fig. 8 A). Unlike COX-1 and p12-LOX derived eoxPL, these 
lipids did not elevate on thrombin activation and were present basally (fig. S3). It is also 
noteworthy that COX-1 eoxPL in this group are exclusively plasmalogen species, while 
p12-LOX-derived include both acyl and plasmalogen forms as well as PC and PE.  
 
 
 
Discussion 
Herein, we show using in vitro coagulation studies, murine venous thrombosis 
models and molecular dynamics simulations that HETE-PLs increase calcium/PS-
dependent factor activities in vitro and in vivo (Figs. 1 to 4).  Coagulation factors 
associate with anionic phospholipids (classically native PS and PE) via interactions with 
positively charged calcium ions. Positioning the HETE hydroxyl group near the 
membrane surface appears to enhance this, and provides a mechanistic basis (Fig. 2).  
Mice lacking either 12/15-LOX (leukocyte type) or p12-LOX (platelet type) were affected 
in venous bleeding challenge models, indicating that both LOX isoforms likely act in 
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concert to achieve effective hemostasis in vivo (Fig. 4). Circulating blood cells from 
patients with the thrombotic disorder APS had significantly higher amounts of leukocyte 
and platelet-derived eoxPL basally, in concert with elevated anti-HETE-PL 
immunoreactivity (Figs. 5 to 6).  Furthermore, by undertaking a comprehensive lipidomics 
analysis of platelets from APS patients and controls, a complex network of 
independently-regulated eoxPL families from COX-1 and p12-LOX was revealed (Figs. 7 
to 8). A large group of platelet lipids, generated via p12-LOX, were significantly elevated 
in APS (Fig. 8B). Together, this suggests a contribution of eoxPL from this pathway to 
human thrombotic disease via their procoagulant or immunogenic activities, but this 
remains to be conclusively proven.  The clear stratification of lipids into groups that 
behaved differently based on headgroup, Sn2 fatty acid or Sn1 acyl/plasmalogen 
composition shown by the clustering/network analyses suggests additional enzymatic 
regulation mechanisms for eoxPL formation and metabolism in platelets, that remain to 
be characterized.  These could include differential enzymatic control of acylation of the 
oxidized fatty acids into specific lysoPL species. In this regard, little is yet known about 
fatty acyl CoA ligase or lysophospholipid acyl-transferase isoform preference for different 
oxidized fatty acids or eicosanoids as substrates for esterification, in platelets or any cell 
type. 
Previous studies proposed a role for lipid oxidation in APS since non-enzymatic 
oxidation products increase in urine (28).  We suggest that this may be initiated by 
leukocyte and platelet LOXs, with primary enzymatic oxidation products such as 
peroxides and lipid radicals decomposing and mediating propagation reactions non-
enzymatically. While there are numerous antigenic targets for antiphospholipid 
antibodies, only some have been implicated in APS (29,30).  Further study is necessary 
to determine whether HETE-PE-specific antibodies are causally involved, however 
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elevated IgG indicates that the lipids will be chronically elevated in APS patients with 
thrombotic disease.  
A mechanism proposed to promote thrombosis in APS involves increased binding 
of β2GPI to PF4, causing platelet activation measured by elevated in vivo TXB2 (31-33).  
In this regard, we found HETE-PEs facilitated increased β2GPI binding to membranes, 
both directly and via enhancing cardiolipin-dependent binding, and also observed 
elevated TXB2 in vivo in our cohort (Fig. 5E, 6, D and E). Additionally, APS monocytes 
can promote both coagulation and inflammation via elevated tissue factor (TF), TNFa and 
IL-1 generation (34,35). It is known that β2GPI binding to monocytes in complex with 
anti-β2GPI IgG increases TF (36). Thus, our studies suggest two potential mechanisms 
for elevated thrombosis linked to eoxPL: (i) direct HETE-PL enhancement of PS-
dependent coagulation on the platelet or leukocyte surface, by mechanisms 
characterized herein, and (ii) increased β2GPI binding to oxidized phospholipids on the 
surface of circulating immune cells, which then goes on to promote inflammation and TF 
expression. Further work is required to determine the relative contribution of these to 
APS. We also noted a significant elevation in the neutrophil 5-LOX-derived 5-HETE-PE 
and 5-HETE-PE IgG indicating that these cells circulate in an activated state in APS 
(Figs. 5B, 6B) (37). Since 5-HETE-PE also increased cardiolipin-dependent b2GPI 
membrane binding, potentially mimicking apoptosis, this could enhance neutrophil 
activation and clearance already known to occur in APS (Fig. 6E) (38).  
Coagulation factors FII, VII, IX and X contain Gla domains, specialized regions 
that contain post-translational modifications of many glutamate residues by vitamin K-
dependent carboxylation to form γ-carboxyglutamate. These mediate a high-affinity 
interaction of calcium with aPL on the cell surface, in particular PS and PE (2,23). The 
cofactors FVIII and FV bind negatively charged phospholipids via the homologous C1 
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and C2 domains. HETE-PLs enhanced coagulation in vitro and in vivo (Figs. 1,3,4). It is 
well known that native PC alone does not support coagulation, since its bulky head group 
inhibits Gla domain interactions with its phosphate (2). However, in multiple experiments 
in vitro and in vivo, HETE-PC promoted coagulation (Fig. 1, D to F, 3A). Most previous 
studies have focused on the head group, however PLs also differ with respect to fatty 
acid composition (3,26). Thus, the action of eoxPL is entirely dependent on the oxidized 
epitope. This represents a paradigm shift in our understanding of hemostasis, whereby 
certain forms of PC rapidly generated by activated leukocytes and platelets promote 
clotting. Dissecting out which specific factors and co-factors are sensitive to HETE-PLs 
will be undertaken using recombinant factors and surface plasmon resonance in a follow-
on study.  
HETE-PLs directly enhanced PS-dependent thrombin generation, suggesting they 
act similarly to native PE via calcium binding (Fig. 1, G to J). Our molecular dynamics 
simulation strongly supports this (Fig. 2). The HETE-hydroxyl group quickly moved on to 
the surface of the membrane, where it is able to interact with calcium. It also widened the 
distance between headgroups allowing greater accessibility to phosphate. To some 
extent, the effect of HETE-PL mimics the role of the carboxylic acid of the PS headgroup, 
which offers an anchor to calcium, and this was backed by showing increased calcium 
association with HETE-PE liposomes (Fig. 2F).  
This process also provides a potential explanation for elevated β2GP1 binding. 
Cardiolipin is negatively-charged at pH 7.4.  Although it contains two phosphate groups, 
the pKa values are such that one is protonated and one is not at pH 7.4, giving an overall 
net negative charge.  In a similar way to PS, we hypothesise through pushing upwards, 
the HETE group may allow cardiolipin phosphates to interact more effectively with the 
positively-charged β2GP1.   
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Concentrations of HETE-PLs in thrombinoscope assays ranged from 10 - 100 
ng/ml.  We calculated HETE-PL generation by human or mouse platelets to be 23 ng/4 x 
107, or 35 ng/2 x 108 for human or murine platelets respectively (9) (Fig. 3D). Given 
typical blood platelet concentrations (2 or 4 x 108/ml for human or mouse respectively) 
this would be expected to equate to around 120 ng/ml or 70 ng/ml for mouse or human 
blood. HETE-PE and -PC isomers represent only a small fraction of the total membrane 
oxidation that occurs during platelet activation, with more than 100 individual molecular 
species being formed acutely (13).  Thus the actual concentration of potential pro-
coagulant eoxPLs in the platelet membrane is likely to be considerably higher than our 
estimates. Furthermore, recent studies showed that annexin V binding is clustered to 
discrete domains of the activated platelet membrane, where procoagulant PLs 
concentrate, thus achieving even higher local amounts (39).  
p12-LOX-/- mice show have increased venous tail bleeding (40,41). We show 
herein that hemostasis is restored in both p12- and 12/15-LOX-/- mice through 
administering liposomes that promote clotting factor activities in vitro and elevate TATs in 
vivo. Since liposomes themselves do not aggregate, this indicates they act solely through 
providing a pro-coagulant surface.  These data support the idea that coagulation is 
defective in these mice rather than platelet aggregation (Fig. 4 C,D). The earliest study 
on p12-LOX-/- mice reported normal platelet aggregation to most agonists, with a slight 
hyper-responsiveness to ADP, indicating no functional deficit (42). Venous thrombosis as 
studied herein, is predominantly dependent on coagulation, rather than platelet function.  
In this regard, APS venous thrombosis responds best to anticoagulation (e.g. warfarin, 
heparin) but less well to antiplatelet therapies (aspirin, clopidogrel). While our data 
suggest that eoxPL contribute to the thrombotic phenotype in APS in the absence of 
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orally active LOX inhibitors, and with the patients on oral anticoagulant therapy, it is not 
currently possible to test this conclusively.  
We used oxPL generated by chemical/air oxidation that were purified using HPLC, 
since it is not currently possible to use enzymes to generate sufficient amounts for 
biological studies (except for 15-HETE-PE).  Regardless of how the lipids are generated, 
they will be virtually identical, with the only difference being enantiomeric composition.  
Specifically, mammalian immune cell LOXs generate the S enantiomer, while 
air/chemical oxidation will result in an approximate 50:50 mixture of S and R 
enantiomers.  In the case of our biological studies, where pro-coagulant activity is not 
based on a receptor dependent effect and is instead related to electronegative character, 
we do not expect S or R enantiomers to differ.  Indeed, our observation that several 
positional isomers and both PE and PC forms were pro-coagulant supports this idea.    
In summary, we demonstrate families of eoxPL elevated during APS that provide 
an immunogenic target, a binding site for β2GPI, and can promote coagulation in vitro 
and in vivo. We also characterize the mechanism by which they enhance coagulation, 
and show their ability to support normal hemostasis in mice. Using lipidomics and 
correlation networks we uncover enzymatic control pathways for multiple families of 
eoxPLs generated by activated platelets.  The findings define mechanisms by which 
physiological membrane oxidation regulates innate immune cell function during acute 
activation/inflammation, as well as potentially leading to new diagnostic tools or 
treatments for bleeding or thrombotic disease.  
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Materials and Methods 
 
Materials. HETE-PEs and –PCs were generated and purified as previously described 
(43). All other reagents are listed in Supplementary Methods. 
 
Study Design. All studies were carried out in accordance with the principles of the 
Declaration of Helsinki and with informed consent and full ethical approval, as detailed in 
Methods. Antiphospholipid syndrome: The study was approved by the South West Wales 
Research Ethics Committee (12/WA/0229). Full information on patients and 
inclusion/exclusion criteria is in Supplementary Data1. Blood donations from healthy 
volunteers were approved by the Cardiff University School of Medicine Ethics Committee, 
and were with informed consent (SMREC 12/37, SMREC 12/10). A power calculation 
was not undertaken as preliminary data was not available for our studies. Rules for 
stopping data collection were not defined.  Outliers were not removed and endpoints 
were not prospectively selected. Replicates for all experiments are included in figure 
legends. The objectives of the research were to define whether eoxPL were able to 
modulate coagulation reactions, determine mechanisms involved and examine whether 
they are elevated in human thrombotic disease.  Research subjects included patients 
with APS (total number 18) and healthy controls (total number 34), mice (wild type and 
genetically modified) and liposomes of defined composition.  There were several different 
studies in our design, including controlled laboratory experiments and observational 
studies.  Treatments, types of observations and measurement techniques are all outlined 
below and in Supplementary Methods. Randomization is not relevant as we did not 
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conduct a clinical trial.   Blinding was used during analysis of lipids from patients and 
controls, but not in animal, cellular or liposome experiments.   
 
Generation of liposomes. Liposomes were made by freeze thaw, followed by extrusion in 
20 mmol/L HEPES, 100 mmol/L NaCl, pH 7.35 (buffer A). Where HETE-PE was 
substituted for unoxidized PE, the liposomes were: 5 % SAPS, 20-30 % SAPE, 0-10 % 
HETE-PE and 65 % DSPC (mol %). Where unoxidized PC was substituted for HETE-PC 
the liposomes were: 5 % SAPS, 30 % SAPE, 55 % DSPC, 0-10 % SAPC and 0-10 % 
HETE-PC. Liposomes were made in the presence of 10 pmol/L full length recombinant 
TF, and used at a final concentration of 4 µM total lipid unless otherwise stated. Binding 
of β2GP1 to liposomes was determined as described in Supplementary Methods.  
 
Thrombin generation assays. Thrombin generation assays were performed using a 
Fluoroskan Ascent plate reader (ThermoLabsystems, Helsinki, Finland). Cleavage of 
prothrombin to thrombin was measured using 0.5 mmol/L fluorogenic substrate Z-Gly-
Gly-Arg-AMC and thrombin activity compared to thrombin calibrator (Stago). Thrombin 
generation was calculated from raw fluorescence data (44). Cleavage of prothrombin to 
thrombin in simplified coagulation cascade experiments was performed according to the 
same methods but using a mixture of FII (1.4 µmol/L), FV (26 nmol/L), FVII (10 nmol/L), 
FVIII (300 pmol/L), FIX (80 nmol/L) and FX (136 nmol/L) was used in buffer A with 1 % 
BSA (buffer B). The reaction was initiated by addition of CaCl2 (20 mmol/L) and 
fluorogenic substrate (0.5 mmol/L) in buffer B.  
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Lipid extraction and analysis. 1,2-dimyristoyl-PE or -PC (10 ng) was added to each 
sample before extraction as an internal standard. Lipids were extracted by adding a 
solvent mixture (1 M acetic acid, 2-propanol, hexane (2:20:30)) to the sample at a ratio of 
2.5 ml solvent mixture to 1 ml sample, vortexing and then adding 2.5 ml of hexane.  
Following vortexing and centrifugation (400 g, 5 mins), lipids were recovered in the upper 
hexane layer.  The samples were then re-extracted by the addition of an equal volume of 
hexane followed by further vortexing and centrifugation.  The combined hexane layers 
were then dried under vacuum and analyzed for HETE-PE using LC/MS/MS. Samples 
were separated on a C18 Luna, 3 µm, 150 mm x 2mm column (Phenomenex) gradient of 
50-100 % B over 10 min followed by 30 min at 100 % B (Solvent A: 
methanol:acetonitrile:water, 1 mM ammonium acetate, 60:20:20. Solvent B: methanol, 1 
mM ammonium acetate) with a flow rate of 200 µl/min. Electrospray mass spectra were 
obtained on a Q-Trap instrument (Applied Biosystems 4000 Q-Trap) operating in the 
negative mode.   Products were analyzed in the MRM mode monitoring transitions from 
the parent ion to daughter ion of 179.1 (12 HETE [M-H]-) every 200 ms with a collision 
energy of -45-42V.  The area under the curve for the parent to 179.1 was integrated and 
normalized to the internal standard for 16:0p, 18:1p/ 18:0p and 18:0a/12-HETE-PEs.  For 
quantification of these lipids, standard curves were generated with purified 18:0a/12-
HETE-PE/PC.  Where large numbers of HETE-PLs were measured in lipidomics assays, 
fold changes relative to PE or PC internal standards were determined using MRM 
transitions recently published (13).  
 
Determination of circulating antibodies to HETE-PEs.  Specific Ab titres to individual 
HETE-PEs were determined by chemiluminescent ELISA as previously described, with 
further details in Supplementary Methods (45).   
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Isolation of human washed platelets. Washed platelets were prepared from whole blood 
drawn from a central venous catheter into syringes containing acidified citrate dextrose 
(ACD; 85 mM trisodium citrate, 65 mM citric acid, 100 mM glucose) at a ratio of 8.1 parts 
whole blood to 1.9 parts ACD, as described previously (46), and resuspended in modified 
Tyrode’s buffer (134 mM NaCl, 12 mM NaHCO3, 2.9 mM KCl, 0.34 mM Na2HPO4, 1.0 
mM MgCl2, 10mM HEPES, 5mM glucose, pH 7.4) at 2 x 108/mL.  1 ml platelets was 
incubated at 37 oC for 30 min with 1 mM CaCl2, 0.2 U/mL human thrombin (Sigma-
Aldrich, UK) or modified Tyrode’s buffer.  
 
 
Isolation and activation of human leukocytes, and murine platelets. Leukocytes were 
prepared from whole blood drawn from a venous catheter with full details in 
Supplementary Methods. Leukocytes were isolated from 20 ml citrate anticoagulated 
whole blood. Leukocytes were activated at 37 °C with 10 µM A23187 in the presence of 1 
mmol/CaCl2, for 30 min. Mouse platelets were isolated as described in Supplementary 
Methods, then activated with 0.2 U/ml thrombin and 1 mM CaCl2 followed by gentle 
mixing every 2 - 3 min for 30 min at 37 °C.  
 
Isolation of serum, plasma and urine. Full details are provided in Supplementary 
Methods. 11-dehyro-TxB2 was measured using GC/MS as previously described (47). 
Plasma thrombin-antithrombin complexes were determined using a commercial ELISA as 
in Supplementary Methods.  
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Quantification of blood loss from tail bleeding assays.  C57/BL6 wild type (Charles River), 
12/15-LOX-/- and p12-LOX-/- mice bred in-house were kept in constant temperature cages 
(20 – 22 °C) and given free access to water and standard chow. Tail bleeding assays and 
breeding of mice was performed under Home Office License PPL/3150. Full details on 
procedure, liposome composition and blood loss measurements are given in 
Supplementary Methods. 
 
Injury-related venous thrombosis. Thrombosis was induced as described previously with 
minor modifications (48), as described in Supplementary Methods.  
 
Lipid Bilayer Model Preparation, and membrane energy minimization and simulation 
protocol.  A pre-equilibrated hydrate lipid bilayer consisting of 128 molecules of 1,2-
Dioleoyl-sn-glycero-3-phosphocholine (DOPC), based on a previously reported study, 
was downloaded from the ATM database (Box ID: 30) (49,50). Full details of the protocol 
are provided in Supplementary Methods.   
 
Measurement of calcium binding to membranes.  Binding of calcium to lipids was 
determined by competition with a calcium probe, Fluo-FF, as described in Supplementary 
Methods.  
 
Heatmap and Cytoscape correlation.  Heatmaps were generated using the pheatmap 
package in R (version 3.3.1). Data was first normalised to the mean of the unstimulated 
control values for each lipid. Network analysis was performed with Cytoscape (version 
3.4.0), utilizing pairwise correlations between lipids generated with R. The network 
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diagram shows only correlations with a Pearson product-moment correlation coefficient 
value (r) > 0.8, due to the high number of interactions. 
 
Statistics 
Statistical significance was calculated using Mann Whitney U test, unless otherwise 
stated. The statistical differences between β2GPI binding to HETE-PL and cardiolipin 
liposomes were calculated using one-way ANOVA with Tukey-Kramers  multi comparison 
post hoc test, used to compare the means of each condition.  p values of < 0.05 were 
considered significant (*), values of p < 0.01 considered highly significant (**), with values 
of p <0.001 considered exceptionally significant (***). Statistical analysis was performed 
using Graphpad Prism 6.  Unless otherwise stated in figure legends, data displayed as 
tukey boxplots, where whiskers represent 1.5 the lower and upper interquartile range, 
data not included within the whiskers is displayed as individual outliers. The correlation 
plot (Fig. 7B) was created in R using the corrplot package (51,52).  
 
List of Supplementary Materials:  
Supplementary Data.docx (full description of methods that could not be included due to 
word limits and supplementary figs S1 to S4: bar charts for all lipids measured in APS or 
12-LOX-/- study, additional correlation plots, analysis of patient demographics) 
lipid simulation.avi (movie showing 300 ns simulation of 12-HETE-PC in a membrane) 
statsletter.doc (email from Dr Farewell confirming stats). 
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Figure Legends 
Figure 1. HETE-PE/PCs dose dependently enhance TF-dependent thrombin 
generation through a PS-dependent mechanism.  Thrombin generation was initiated 
by addition of liposomes to pooled platelet poor plasma (PPP) as described in Methods, 
using a thrombinoscope.  Panels A-C. HETE-PEs enhance TF-dependent coagulation in 
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plasma. Liposomes contained 10 pM recombinant TF with 65 % DSPC, 5 % SAPS and 
30 % SAPE, with 0 – 10 % SAPE replaced with 0 – 10 % HETE-PE. (A) 5-HETE-PE, (B) 
12-HETE-PE, (C) 15-HETE-PE.  Panels D-F. HETE-PCs enhance TF-dependent 
coagulation in plasma. Liposomes contained 10 pM TF, 55 % DSPC, 5 % SAPS, 30 % 
SAPE, with 0 – 10 % SAPC replaced with < 10 % HETE-PC. (D) 5-HETE-PC, (E) 12-
HETE-PC, (F) 15-HETE-PC. Representative traces are shown of experiments repeated 
at least 3 times.  Panels G-J. 15-HETE-PE/PC enhances PS-dependent thrombin 
generation. Pooled PPP was activated using liposomes, as above, where SAPE was 
replaced with 15-HETE-PE/PC, with/without SAPS (replacing PC) as indicated on the 
figure. Representative traces (Panel G, I) and maximum thrombin at varying PS 
concentration (Panel H, J) are shown (n = 3 runs, mean ± SEM).  Panels K-M. HETE-
PE/PCs promote activities of coagulation factors in a full reconstitution system. Thrombin 
generation was initiated by addition of liposomes to purified factors II, V, VII, VIIII, IX, X at 
physiological concentrations, as described in Methods. Liposomes contained (Panel K) 
65 % DSPC, 5 % SAPS, 30 % SAPE, with 10 % SAPE (control) or 10 % HETE-PE or 
(Panel L) 55 % DSPC, 5 % SAPS, 30 % SAPE, 10 % SAPC (control) or 10% HETE-PC. 
Panel M shows summary data showing fold-change for the maximum thrombin 
generation rate observed (slope of lines in K,L) for each isomer (n = 3 runs, mean ± 
SEM). **  p<0.01, * : p<0.05, single-factor ANOVA and post-hoc Tukey tests.  
 
Figure 2. Molecular dynamics simulation demonstrates association of the HETE-PL 
hydroxyl group with the polar environment, serine and calcium ions, while HETE-
PL membranes bind more calcium.  Panels A-E. Molecular dynamics shows HETE –
OH group altering membrane behavior.  Molecular simulations were undertaken for 300 
ns using 5% SAPS, 5% SAPC, 30% SAPE, 55% DOPC, 5% 12-HETE-PC as described 
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in Methods.  Panels A-D. Side views showing hydrophobic (yellow), charged phosphate 
groups (cyan) and PC headgroups (grey).  Note bending of HETE with association of –
OH groups with membrane surface (Panels A), as well with calcium (Panel B,C) and the 
PS headgroup (Panel D).  Panel E. Top view looking down on membrane showing areas 
of positive charge (blue), negative charge (brown), PS headgroups (pink) and HETE 
hydroxyl groups (red).  Note that all three PS and HETE –OH groups are visible (labeled) 
from above. Panel F.  Binding of calcium to membranes is increased by 15-HETE-PE. 
Liposomes comprising 65 % DSPC, 30 % SAPE, and 5 % SAPS, with up to 10 % SAPE 
replaced by 15-HETE PE were tested for calcium binding using by Fluo-FF fluorescence, 
as described in Methods. **p<0.01 and *p<0.05 show significance compared to no added 
15-HETE PE (n = 3 separate samples, mean ± SEM).  
 
Figure 3. HETE-PL liposomes prevent tail bleeding and elevate TAT levels in vivo, 
while platelets from mice genetically lacking p12-LOX fail to generate numerous 
eoxPL.  Panel A 12-HETE-PE/TF intra-dermal administration prevents tail bleeding in 
adult mice. 11-week old male C57BL/6J mice were injected with liposomes containing TF 
with or without 12-HETE-PE or -PC, immediately proximal of a tail cut, and bleeding time 
and blood loss recorded as in Methods (n = 10 - 16 mice per group). ** p ≤ 0.01, * p ≤ 
0.05. Mann Whitney U test Panel B. 12-HETE-PE elevates thrombin-anti-thrombin (TAT) 
complexes in vivo.  Control or HETE-PE-containing liposomes were injected i.v. into wild 
type mice and plasma obtained after 1 hr.  TAT levels were measured using ELISA as 
described in Methods (n = 6 mice per group, * p ≤ 0.05). Panel C. Murine washed 
platelets generate several eoxPL on thrombin activation, that are absent in p12-LOX-
deficiency.  Murine washed platelets were activated for 30 min using 0.2 U/ml thrombin, 
then lipids extracted and analyzed for eoxPL as described in Methods (n = 3, mean). 
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Heatmap was generated as described in Methods using the pheatmap package in R.  
Panel D.  Time course of generation of 12-HETE-PEs and –PCs shows lipids continue to 
elevate up to at least 30 min post activation.  Platelets from wild-type or 12-LOX-/- mice (2 
x 108/ml) were activated using 0.2 U/ml human thrombin for 0 - 30 min at 37 °C, and 
lipids then extracted and quantified as described in Methods. HETE-PE represents the 
sum of 16:0p/12-HETE-PE, 18:1p/12-HETE-PE, 18:0/12-HETE-PE, and 18:0a/HETE PE. 
HETE-PC represents the sum of 16:0a/12-HETE-PC and 18:0a/12-HETE-PC (mean ± 
SEM, n = 8 mice). 
 
Figure 4. Mice lacking either 12/15- or p12-LOX have impaired venous coagulation 
in vivo, that can be restored using 12-HETE-PE liposome administration.   Panels 
A,B.  p12-LOX deficient mice show lower thrombus formation in vivo following challenge.  
Venous thrombosis was induced in vivo in p12-LOX-/- mice as described in Methods (n = 
7-9 mice per group).  A representative thrombus is shown. Panel C.  p12-LOX deficient 
mice have impaired hemostasis in vivo. 8-11 week old male wild type C57BL/6J or p12-
LOX-/- mice were administered a tail cut, and bleeding time and blood loss recorded as in 
Methods. Liposomes containing 19 ng 12-HETE-PE or control liposomes were 
administered in 10 ml PBS, just upstream of the cut, and immediately beforehand (n = 6 
– 12 mice per group ** p ≤ 0.01).  Panel D.  12/15-LOX deficient mice have impaired 
hemostasis in vivo. As for Panel C, 8 - 11 week old male wild type C57BL/6J or 12/15-
LOX-/- mice were administered a tail cut with/without liposomes, and bleeding time and 
blood loss recorded as in Methods (n = 12 – 19 mice per group, ** p ≤ 0.01), Mann 
Whitney U test .   
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Figure 5. HETE-PEs are elevated in APS leukocytes and platelets. HETE-PEs were 
quantified as individual molecular species then combined.  Panels A,B. 15- and 5-
HETE-PEs are elevated in leukocytes from APS patients. Total leukocytes isolated as 
described, were stimulated at 4 x 106 cells/ml with 10 mM A23187 for 30 mins at 37 °C, 
then lipids analyzed for HETE-PEs as described in Methods (n = 34 (HC, Healthy 
controls), 17 (APS) people). Panel C. 12-HETE-PEs are elevated in APS platelets. 
Washed platelets were isolated and stimulated with 0.2 U/ml thrombin for 30 min at 37 °C 
as described in methods (n = 18 (HC), 12 (APS) people).  Panel D. APS platelets that 
spontaneously aggregated contain high levels of 12-HETE-PEs.  During the final washing 
step, a number of APS platelet isolates spontaneously aggregated (n = 7 patients). Lipids 
were extracted and analyzed for 12-HETE-PEs as in Methods.  Panel E. Urinary TXB2 is 
elevated in APS.  Urine was extracted as described in Methods before GC/MS analysis 
as described in Methods (n = 32 (HC), 9 (APS)). Panels F,G. Leukocyte-derived 15- and 
5-HETE-PEs are elevated basally in APS platelets.  Platelets were prepared as in Panel 
C, then analyzed for HETE-PEs (n = 18 (HC), 12 (APS) people). Panel H. Platelet 
derived 12-HETE-PEs are elevated basally in APS leukocytes.  Total leukocytes were 
isolated and stimulated at 4 x 106 cells/ml with 10 mm A23187 for 30 min at 37°C and 
then analyzed for 12-HETE-PEs as described in Methods (n = 34 (HC), n = 18 (APS) 
people), (*** p ≤ 0.001, ** p ≤ 0.01, * p ≤ 0.05), Mann Whitney U test . 
 
Figure 6. Circulating IgG against HETE-PEs are elevated in APS and b2BP1 binding 
to membranes is enhanced by HETE-PEs Panels A-C. IgG against HETE-PEs are 
significantly elevated in APS plasma.  Levels of IgG antibodies to HETE-PEs were 
determined by diluting plasma 1:12 and testing binding to the indicated antigens as 
described in Methods. SAPE was used as unoxidized lipid comparison. All samples were 
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analyzed in triplicate (n = 18 (HC), n = 9 (APS) people). * p < 0.05, ** p 0.01, Mann 
Whitney U test Panel D. IgG titers are comparable in healthy control and patient plasma. 
Total IgG was determined in plasma from patients with APS and healthy controls (n = 34 
(HC), n = 10 (APS) people).  Panel E. HETE-PEs enhance b2GPI binding to lipid 
membranes. Binding of b2GPI to liposomes in the presence of cardiolipin or 15-HETE-
PE, 5-HETE-PE or 12-HETE-PE alone was determined as described in Methods. Panel 
F. HETE-PEs enhance cardiolipin-dependent b2GPI binding to lipids. Binding of b2GPI to 
liposomes in the presence of cardiolipin with/without 15-HETE-PE, 5-HETE-PE or 12-
HETE-PE was determined as in Panel E. For Panels D,E, n = 3 separate experiments, 
each in triplicate. mean ± SEM. Significance was determined using one-way ANOVA, 
Tukey-Kramers test * p < 0.05, ** p 0.01, *** P <0.001. 
 
Figure 7. Lipidomic profiling of 47 eoxPL defines their enzymatic origin and 
regulatory networks.  Washed platelets were isolated from healthy controls or APS 
patients and activated using thrombin (0.2 U/ml, 30 min) before lipid extraction and 
analysis using LC/MS/MS for 47 eoxPL as described in Methods (n = 16 HC, 10 APS 
people).  Panel A. p12-LOX and COX-1 derived lipids cluster into distinct families based 
on Sn2 fatty acid composition.  A heatmap showing effect of thrombin on individual lipid 
levels was generated using the pheatmap package in R using hierarchical clustering 
(complete linkage method) to group similar lipids. Panel B. Plotting correlation between 
individual lipids illustrates additional relatedness between families of ions.  Correlations 
between lipids across the whole cohort were plotted in a grid, in order of decreasing 
correlation with 18:0a/12-HETE-PE, as described in Methods.  Red: p12-LOX, blue: 
COX-1, green: polyoxygenated PL, black: unknown origin.  Red arrows identify a group 
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of 6 lipids (almost all acyl with 22:5(O) or 22:4(O) at Sn2) that correlate as a group 
suggesting relatedness.    
 
Figure 8.  Cytoscape network confirms enzymatic origin of lipids, and identifies an 
additional group regulated independently of known pathways, and p12-LOX 
derived eoxPL are significantly elevated in APS platelets.  Panel A.  A Cytoscape 
network correlation identifies three groups of eoxPL.  Cytoscape 1.2.3 correlation was 
performed (correlation > 0.8) using data shown in Figure 7A, with nodes as individual 
lipids and degree (size) determined by number of links to others.  Edge thickness 
represents correlation between individual nodes. Lipids were identified as COX-1 or p12-
LOX derived based on aspirin sensitivity or their absence in p12-LOX-/- mice, as 
described in Results.  Panel B. p12-LOX lipids are significantly elevated in APS, as a 
group either with/without thrombin activation.  Platelet lipids identified as originating from 
p12-LOX (n=31) or COX-1 (n=9) as determined using the Cytoscape network were 
examined as separate groups for significant differences between healthy controls and 
APS patients using Mann-Whitney U, * p < 0.05, ** p 0.01, *** P <0.001.  
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Figure	1.	HETE-PE/PCs	dose	dependently	enhance	TF-dependent	thrombin	genera>on	through	a	PS-dependent	mechanism.		
Thrombin	genera-on	was	ini-ated	by	addi-on	of	liposomes	to	pooled	platelet	poor	plasma	(PPP)	as	described	in	Methods,	using	
a	thrombinoscope.		Panels	A-C.	HETE-PEs	enhance	TF-dependent	coagula8on	in	plasma.	Liposomes	contained	10	pM	
recombinant	TF	with	65	%	DSPC,	5	%	SAPS	and	30	%	SAPE,	with	0	–	10	%	SAPE	replaced	with	0	–	10	%	HETE-PE.	(A)	5-HETE-PE,	(B)	
12-HETE-PE,	(C)	15-HETE-PE.		Panels	D-F.	HETE-PCs	enhance	TF-dependent	coagula8on	in	plasma.	Liposomes	contained	10	pM	TF,	
55	%	DSPC,	5	%	SAPS,	30	%	SAPE,	with	0	–	10	%	SAPC	replaced	with	<	10	%	HETE-PC.	(D)	5-HETE-PC,	(E)	12-HETE-PC,	(F)	15-HETE-
PC.	Representa-ve	traces	are	shown	of	experiments	repeated	at	least	3	-mes.		Panels	G-J.	15-HETE-PE/PC	enhances	PS-
dependent	thrombin	genera8on.	Pooled	PPP	was	ac-vated	using	liposomes,	as	above,	where	SAPE	was	replaced	with	15-HETE-
PE/PC,	with/without	SAPS	(replacing	PC)	as	indicated	on	the	ﬁgure.	Representa-ve	traces	(Panel	G,	I)	and	maximum	thrombin	at	
varying	PS	concentra-on	(Panel	H,	J)	are	shown	(n	=	3	runs,	mean	±	SEM).		Panels	K-M.	HETE-PE/PCs	promote	ac8vi8es	of	
coagula8on	factors	in	a	full	recons8tu8on	system.	Thrombin	genera-on	was	ini-ated	by	addi-on	of	liposomes	to	puriﬁed	factors	
II,	V,	VII,	VIIII,	IX,	X	at	physiological	concentra-ons,	as	described	in	Methods.	Liposomes	contained	(Panel	K)	65	%	DSPC,	5	%	SAPS,	
30	%	SAPE,	with	10	%	SAPE	(control)	or	10	%	HETE-PE	or	(Panel	L)	55	%	DSPC,	5	%	SAPS,	30	%	SAPE,	10	%	SAPC	(control)	or	10%	
HETE-PC.	Panel	M	shows	summary	data	showing	fold-change	for	the	maximum	thrombin	genera-on	rate	observed	(slope	of	lines	
in	K,L)	for	each	isomer	(n	=	3	runs,	mean	±	SEM).	**		p<0.01,	*	:	p<0.05,	single-factor	ANOVA	and	post-hoc	Tukey	tests.		
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Figure	2.	Molecular	dynamics	simula>on	demonstrates	associa>on	of	the	HETE-PL	hydroxyl	group	with	the	polar	environment,	
serine	and	calcium	ions,	while	HETE-PL	membranes	bind	more	calcium.		Panels	A-E.	Molecular	dynamics	shows	HETE	–OH	group	
altering	membrane	behavior.		Molecular	simula-ons	were	undertaken	for	300	ns	using	5%	SAPS,	5%	SAPC,	30%	SAPE,	55%	DOPC,	
5%	 12-HETE-PC	 as	 described	 in	Methods.	 	 Panels	 A-D.	 Side	 views	 showing	 hydrophobic	 (yellow),	 charged	 phosphate	 groups	
(cyan)	and	PC	headgroups	(grey).	 	Note	bending	of	HETE	with	associa-on	of	–OH	groups	with	membrane	surface	(Panels	A),	as	
well	with	calcium	(Panel	B,C)	and	the	PS	headgroup	(Panel	D).	 	Panel	E.	Top	view	looking	down	on	membrane	showing	areas	of	
posi-ve	charge	(blue),	nega-ve	charge	(brown),	PS	headgroups	(pink)	and	HETE	hydroxyl	groups	(red).		Note	that	all	three	PS	and	
HETE	 –OH	 groups	 are	 visible	 (labeled)	 from	 above.	 Panel	 F.	 	 Binding	 of	 calcium	 to	 membranes	 is	 increased	 by	 15-HETE-PE.	
Liposomes	 comprising	 65	%	DSPC,	 30	%	 SAPE,	 and	5	%	 SAPS,	with	up	 to	 10	%	 SAPE	 replaced	by	15-HETE	PE	were	 tested	 for	
calcium	binding	using	by	Fluo-FF	ﬂuorescence,	as	described	in	Methods.	**p<0.01	and	*p<0.05	show	signiﬁcance	compared	to	no	
added	15-HETE	PE	(n	=	3	separate	samples,	mean	±	SEM).		
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Figure	3.	HETE-PL	liposomes	prevent	tail	bleeding	and	elevate	TAT	levels	in	vivo,	while	platelets	from	mice	gene>cally	lacking	
p12-LOX	fail	to	generate	numerous	eoxPL.	 	Panel	A	12-HETE-PE/TF	intra-dermal	administra8on	prevents	tail	bleeding	in	adult	
mice.	 11-week	 old	 male	 C57BL/6J	 mice	 were	 injected	 with	 liposomes	 containing	 TF	 with	 or	 without	 12-HETE-PE	 or	 -PC,	
immediately	proximal	of	a	tail	cut,	and	bleeding	-me	and	blood	loss	recorded	as	in	Methods	(n	=	10	-	16	mice	per	group).	**	p	≤	
0.01,	*	p	≤	0.05.	Mann	Whitney	U	test	Panel	B.	12-HETE-PE	elevates	thrombin-an8-thrombin	(TAT)	complexes	in	vivo.		Control	or	
HETE-PE-containing	liposomes	were	injected	i.v.	into	wild	type	mice	and	plasma	obtained	aier	1	hr.		TAT	levels	were	measured	
using	ELISA	as	described	in	Methods	(n	=	6	mice	per	group,	*	p	≤	0.05).	Panel	C.	Murine	washed	platelets	generate	several	eoxPL	
on	thrombin	ac8va8on,	that	are	absent	in	p12-LOX-deﬁciency.		Murine	washed	platelets	were	ac-vated	for	30	min	using	0.2	U/
ml	thrombin,	then	lipids	extracted	and	analyzed	for	eoxPL	as	described	in	Methods	(n	=	3,	mean).	Heatmap	was	generated	as	
described	in	Methods	using	the	pheatmap	package	in	R.	 	Panel	D.	 	Time	course	of	genera8on	of	12-HETE-PEs	and	–PCs	shows	
lipids	con8nue	 to	elevate	up	 to	at	 least	30	min	post	ac8va8on.	 	Platelets	 from	wild-type	or	12-LOX-/-	mice	 (2	x	108/ml)	were	
ac-vated	 using	 0.2	U/ml	 human	 thrombin	 for	 0	 -	 30	min	 at	 37	 °C,	 and	 lipids	 then	 extracted	 and	 quan-ﬁed	 as	 described	 in	
Methods.	HETE-PE	represents	the	sum	of	16:0p/12-HETE-PE,	18:1p/12-HETE-PE,	18:0/12-HETE-PE,	and	18:0a/HETE	PE.	HETE-PC	
represents	the	sum	of	16:0a/12-HETE-PC	and	18:0a/12-HETE-PC	(mean	±	SEM,	n	=	8	mice).	
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Figure	4.	Mice	lacking	either	12/15-	or	p12-LOX	have	impaired	venous	coagula>on	in	vivo,	that	can	be	restored	using	12-HETE-
PE	liposome	administra>on.	 	 	Panels	A,B.	 	p12-LOX	deﬁcient	mice	show	lower	thrombus	forma8on	in	vivo	following	challenge.		
Venous	thrombosis	was	induced	in	vivo	in	p12-LOX-/-	mice	as	described	in	Methods	(n	=	7-9	mice	per	group).	 	A	representa-ve	
thrombus	is	shown.	Panel	C.		p12-LOX	deﬁcient	mice	have	impaired	hemostasis	in	vivo.	8-11	week	old	male	wild	type	C57BL/6J	or	
p12-LOX-/-	mice	were	administered	a	tail	cut,	and	bleeding	-me	and	blood	loss	recorded	as	in	Methods.	Liposomes	containing	19	
ng	12-HETE-PE	or	control	liposomes	were	administered	in	10	ml	PBS,	just	upstream	of	the	cut,	and	immediately	beforehand	(n	=	
6	–	12	mice	per	group	**	p	≤	0.01).	 	Panel	D.	 	12/15-LOX	deﬁcient	mice	have	impaired	hemostasis	in	vivo.	As	for	Panel	C,	8	-	11	
week	old	male	wild	type	C57BL/6J	or	12/15-LOX-/-	mice	were	administered	a	tail	cut	with/without	liposomes,	and	bleeding	-me	
and	blood	loss	recorded	as	in	Methods	(n	=	12	–	19	mice	per	group,	**	p	≤	0.01),	Mann	Whitney	U	test	.			
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Figure	5.	HETE-PEs	are	elevated	in	APS	leukocytes	and	platelets.	HETE-PEs	were	quan-ﬁed	as	individual	molecular	species	then	
combined.	 	Panels	A,B.	15-	and	5-HETE-PEs	are	elevated	in	leukocytes	from	APS	pa8ents.	Total	leukocytes	isolated	as	described,	
were	s-mulated	at	4	x	106	cells/ml	with	10	µΜ	A23187	for	30	mins	at	37	°C,	then	lipids	analyzed	for	HETE-PEs	as	described	in	
Methods	(n	=	34	(HC,	Healthy	controls),	17	(APS)	people).	Panel	C.	12-HETE-PEs	are	elevated	in	APS	platelets.	Washed	platelets	
were	isolated	and	s-mulated	with	0.2	U/ml	thrombin	for	30	min	at	37	°C	as	described	in	methods	(n	=	18	(HC),	12	(APS)	people).		
Panel	 D.	 APS	 platelets	 that	 spontaneously	 aggregated	 contain	 high	 levels	 of	 12-HETE-PEs.	 	 During	 the	 ﬁnal	 washing	 step,	 a	
number	of	APS	platelet	isolates	spontaneously	aggregated	(n	=	7	pa-ents).	Lipids	were	extracted	and	analyzed	for	12-HETE-PEs	
as	in	Methods.		Panel	E.	Urinary	TXB2	is	elevated	in	APS.		Urine	was	extracted	as	described	in	Methods	before	GC/MS	analysis	as	
described	 in	 Methods	 (n	 =	 32	 (HC),	 9	 (APS)).	 Panels	 F,G.	 Leukocyte-derived	 15-	 and	 5-HETE-PEs	 are	 elevated	 basally	 in	 APS	
platelets.	 	Platelets	were	prepared	as	 in	Panel	C,	 then	analyzed	 for	HETE-PEs	 (n	=	18	 (HC),	12	 (APS)	people).	Panel	H.	Platelet	
derived	12-HETE-PEs	are	elevated	basally	 in	APS	 leukocytes.	 	Total	 leukocytes	were	 isolated	and	s-mulated	at	4	x	106	cells/ml	
with	10	µm	A23187	for	30	min	at	37°C	and	then	analyzed	for	12-HETE-PEs	as	described	in	Methods	(n	=	34	(HC),	n	=	18	(APS)	
people),	(***	p	≤	0.001,	**	p	≤	0.01,	*	p	≤	0.05),	Mann	Whitney	U	test	.	
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Figure	6.	Circula>ng	IgG	against	HETE-PEs	are	elevated	in	APS	and	β2BP1	binding	to	membranes	is	enhanced	by	HETE-PEs	Panels	
A-C.	 IgG	against	HETE-PEs	are	 signiﬁcantly	elevated	 in	APS	plasma.	 	Levels	of	 IgG	an-bodies	 to	HETE-PEs	were	determined	by	
dilu-ng	plasma	1:12	and	 tes-ng	binding	 to	 the	 indicated	an-gens	as	described	 in	Methods.	SAPE	was	used	as	unoxidized	 lipid	
comparison.	All	samples	were	analyzed	in	triplicate	(n	=	18	(HC),	n	=	9	(APS)	people).	*	p	<	0.05,	**	p	0.01,	Mann	Whitney	U	test	
Panel	D.	IgG	8ters	are	comparable	in	healthy	control	and	pa8ent	plasma.	Total	IgG	was	determined	in	plasma	from	pa-ents	with	
APS	and	healthy	controls	(n	=	34	(HC),	n	=	10	(APS)	people).		Panel	E.	HETE-PEs	enhance	β2GPI	binding	to	lipid	membranes.	Binding	
of	β2GPI	to	liposomes	in	the	presence	of	cardiolipin	or	15-HETE-PE,	5-HETE-PE	or	12-HETE-PE	alone	was	determined	as	described	
in	 Methods.	 Panel	 F.	 HETE-PEs	 enhance	 cardiolipin-dependent	 β2GPI	 binding	 to	 lipids.	 Binding	 of	 β2GPI	 to	 liposomes	 in	 the	
presence	of	cardiolipin	with/without	15-HETE-PE,	5-HETE-PE	or	12-HETE-PE	was	determined	as	 in	Panel	E.	For	Panels	D,E,	n	=	3	
separate	experiments,	each	in	triplicate.	mean	±	SEM.	Signiﬁcance	was	determined	using	one-way	ANOVA,	Tukey-Kramers	test	*	p	
<	0.05,	**	p	0.01,	***	P	<0.001.	
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Figure	 7.	 Lipidomic	 proﬁling	 of	 47	 eoxPL	 deﬁnes	 their	 enzyma>c	 origin	 and	 regulatory	 networks.	 	Washed	 platelets	 were	
isolated	 from	 healthy	 controls	 or	 APS	 pa-ents	 and	 ac-vated	 using	 thrombin	 (0.2	 U/ml,	 30	min)	 before	 lipid	 extrac-on	 and	
analysis	using	LC/MS/MS	for	47	eoxPL	as	described	in	Methods	(n	=	16	HC,	10	APS	people).		Panel	A.	p12-LOX	and	COX-1	derived	
lipids	cluster	into	dis8nct	families	based	on	Sn2	faZy	acid	composi8on.		A	heatmap	showing	eﬀect	of	thrombin	on	individual	lipid	
levels	was	generated	using	the	pheatmap	package	in	R	using	hierarchical	clustering	(complete	linkage	method)	to	group	similar	
lipids.	 Panel	 B.	 Plo[ng	 correla8on	 between	 individual	 lipids	 illustrates	 addi8onal	 relatedness	 between	 families	 of	 ions.		
Correla-ons	between	 lipids	across	 the	whole	 cohort	were	ploqed	 in	a	grid,	 in	order	of	decreasing	 correla-on	with	18:0a/12-
HETE-PE,	as	described	in	Methods.	 	Red:	p12-LOX,	blue:	COX-1,	green:	polyoxygenated	PL,	black:	unknown	origin.	 	Red	arrows	
iden-fy	a	group	of	6	lipids	(almost	all	acyl	with	22:5(O)	or	22:4(O)	at	Sn2)	that	correlate	as	a	group	sugges-ng	relatedness.				
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Figure	8.		Cytoscape	network	conﬁrms	enzyma>c	origin	of	lipids,	and	iden>ﬁes	an	addi>onal	group	regulated	independently	of	
known	 pathways,	 and	 p12-LOX	 derived	 eoxPL	 are	 signiﬁcantly	 elevated	 in	 APS	 platelets.	 	 Panel	 A.	 	 A	 Cytoscape	 network	
correla8on	iden8ﬁes	three	groups	of	eoxPL.	 	Cytoscape	1.2.3	correla-on	was	performed	(correla-on	>	0.8)	using	data	shown	in	
Figure	7A,	with	nodes	as	individual	lipids	and	degree	(size)	determined	by	number	of	links	to	others.	 	Edge	thickness	represents	
correla-on	between	 individual	nodes.	 Lipids	were	 iden-ﬁed	as	COX-1	or	p12-LOX	derived	based	on	aspirin	 sensi-vity	or	 their	
absence	in	p12-LOX-/-	mice,	as	described	in	Results.	 	Panel	B.	p12-LOX	lipids	are	signiﬁcantly	elevated	in	APS,	as	a	group	either	
with/without	 thrombin	ac8va8on.	 	Platelet	 lipids	 iden-ﬁed	as	origina-ng	 from	p12-LOX	 (n=31)	or	COX-1	 (n=9)	as	determined	
using	 the	Cytoscape	network	were	examined	as	 separate	groups	 for	 signiﬁcant	diﬀerences	between	healthy	controls	and	APS	
pa-ents	using	Mann-Whitney	U,	*	p	<	0.05,	**	p	0.01,	***	P	<0.001.		
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Supplementary Methods and Data 
 
Supplementary Methods 
 
Materials. Corn trypsin inhibitor (CTI, recombinant), and full length tissue factor (TF, 
human recombinant) were from Haematologic Technologies Inc). FII Fluorogenic 
substrate (Z-Gly-Gly-Arg-AMC) was from Bachem (St Helens, UK). T-cal 
Thrombinoscope calibrator was from Stago. 1-Stearoyl-2-arachidonoyl-
phosphatidylethanolamine, -phosphatidylcholine and -phosphatidylserine (SAPE, 
SAPC, SAPS) and 1,2-di-stearoyl-phosphatidylcholine (DSPC) were from Avanti Polar 
Lipids. 2,2’-Azobis(4-methoxy-2,4 dimethyl-valeronitrile) (MeOAVM) was from WAKO. 
All other chemicals and lipsofast membranes were from Sigma-Aldrich, except N-methyl 
Benzohydroamic acid (NMBHA), synthesized in-house according to (1).  Solvents were 
from Fisher Scientific.  
 
Study approvals and patient demographics 
Patients (total 18) with APS associated with venous thrombosis were recruited from 
haematology clinics. All had at least one incidence of venous and/or arterial thrombosis 
and tested positive for at least one laboratory criterion (Lupus anti-coagulant and/or high 
anti-cardiolipin IgG titres and/or high anti-β2GPI IgG titres measured on two occasions 
at least 12 weeks apart).  Patients were not taking aspirin, or other non-steroidal anti-
inflammatory  drugs at the time of venepuncture. Most were taking anti-coagulants, e.g. 
warfarin or rivaroxiban, none had diabetes, and only one had high cholesterol at time of 
sampling. Full details on all patients is in Supplementary Table 1, below.  Blood 
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samples were collected from patients following a routine clinical visit, in a quiescent 
state with no clinical thrombotic episode at the time of sampling.  Healthy controls (total 
34) were recruited from the local population, and were excluded if they had a history of 
arterial or venous thrombosis, recurrent fetal loss, cardiac disease or any other chronic 
inflammatory diseases such as rheumatoid arthritis, SLE, diabetes, high cholesterol, 
abnormal renal or liver function, or other diseases that may conflict with the study 
parameters. Individuals within the HC group had not taken aspirin, non-steroidal anti-
inflammatory drugs or any other medication in the preceding 14 days. Informed consent 
was obtained from all participants. Age and gender demographics is given in Table 
Blood samples were collected from APS patients and healthy controls via venepuncture 
from the median cubital vein.  Full blood counts (FBC) were collected, any patients or 
healthy controls with an abnormal FBC at the time of sample collection were 
retrospectively omitted from the study.  Washed platelets and leukocytes were isolated 
and activated as described. Serum, plasma and urine was collected as described.  
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Patient Age Gender AT VT Chol DM medications	relevant	to	vascular	disease 
APS014 27 F N Y N N warfarin,	hydroxychloroquine 
APS015 22 F N Y N N warfarin 
APS029 43 F Y Y N N warfarin,	hydroxychloroquine 
APS030 52 F Y Y N N warfarin 
APS032 79 M N Y Y N warfarin,	propranolol 
APS033 31 F Y Y N N rivaroxiban 
APS040 51 M N Y N N warfarin,	losartan 
APS042 39 F Y N N N warfarin 
APS044 35 M N Y N N 
warfarin,	 amlodipine,	 bendroflumethiazide,	
doxazosin 
APS060 47 F Y Y N N warfarin,	lanzoprazole,	lisinopril,	amlodipine 
APS061 58 F N Y N N None 
APS062 75 F N Y N N warfarin 
APS063 36 F N Y N N rivaroxiban 
APS064 41 M N Y N N rivaroxiban 
APS065 38 F N Y N N rivaroxiban 
APS066 33 F N Y N N enoxaparin 
APS067 55 F N Y N N warfarin 
APS068 58 F N Y N N rivaroxiban 
 
Supplementary Table 1.  Patient demographics.  AT: arterial thrombosis, VT: venous 
thrombosis, Chol: cholesterol lowering medication, DM: Diabetes Mellitis  
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Supplementary Table 2.  Age and gender demographics of study participants  
 
 
Liposome composition for β2GP1 binding experiments:  All liposomes were as 
described above after extrusion, but with the following lipid composition: 55% distearoly-
PC (DSPC), 15 % stearoyl-arachidonyl-PS (SAPS), 10 % stearoyl-arachidonyl-PC 
(SAPC), 1 % stearoyl-arachidonyl-PE-biotin (SAPE-B, generated by reacting NHS-biotin 
with PE and purification using HPLC), 19 % stearoly-arachidonyl-PE (SAPE).  In some 
experiments, an equivalent amount of SAPE was replaced with 1 % 15-, 12- 5-HETE-
PE, and/or 1 % cardiolipin.  
 
 
Determination of circulating antibodies to HETE-PEs.  Specific Ab titres to individual 
HETE-PEs were determined by chemiluminescent ELISA as previously described (3).  
Lipids were coated onto Microfluor plates at 20 µg/ml and subsequently blocked with 
0.5% fish-gelatin in 0.27 mM PBS-0.27 mM EDTA.  EDTA plasma samples (1:12) were 
diluted in PBS-0.27 mM EDTA and incubated for 1 hour at room temperature.  The 
	 5	
bound IgG was measured using an anti-human IgG alkaline phosphatase-conjugated 
secondary antibody (Sigma Aldrich) and LumiPhos 530  (Lumigen, Inc).  Data are 
expressed as the relative light units per 100 ms (RLU/100 ms). 
 
Isolation of human leukocytes. Leukocytes were isolated from 20 ml citrate 
anticoagulated whole blood.  Briefly, 20 ml of whole blood was mixed with 4 ml of 2 % 
citrate and 4 ml of Hetasep (Stem Cell Technologies) and allowed to sediment for at 
least 45 minutes.  The upper plasma layer was recovered and centrifuged at 250 g for 
10 min at room temperature.  The pellet was resuspended in ice-cold 0.4 % trisodium 
citrate/PBS and centrifuged at 250 g for 5 min at 4 °C.  Erythrocytes were removed by 
hypotonic lysis.  Leukocytes were resuspended in Krebs buffer at 4 x 106/ml.  
Leukocytes were activated at 37 °C with 10 µM A23187 in the presence of 1 
mmol/CaCl2, for 30 min, prior to lipid extraction. 
 
Isolation of serum, plasma and urine. Blood was collected into EDTA, Lithium-Heparin, 
or Citrate vacutainers prior to centrifugation at 900 g.  The plasma layer was collected 
and centrifuged again at 900 g to remove any residual platelets.   Plasma was stored at 
-80 °C for use in in vitro assays.  Whole blood was collected into a clot-activating 
vacutainer and centrifuged at 900 g.  The serum was collected and centrifuged again at 
900 g to remove any residual cells.  Serum was stored at -80 °C for use in in vitro 
assays. Urine was collected into universal containers, samples were aliquoted and 
stored at -80 °C until use. 
 
Isolation and activation of mouse washed platelets. Mouse blood was obtained by 
cardiac puncture directly into a syringe containing 150 µl ACD (2.5% w/v trisodium 
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citrate, 1.5 % w/v citric acid, 100 mM glucose).  The syringe was emptied into an 
eppendorf containing 150 µl 3.8 % w/v sodium citrate, and 300 µl of modified Tyrode’s 
buffer was then added (145 mM NaCl, 12 mM NaHCO3, 2.95 mM KCl, 1 mM MgCl2, 10 
mM HEPES, 5 mM Glucose). The blood was spun for 5 min at 150g at 25°C, and 
platelet-rich-plasma (PRP) removed. Another 400 µl of Tyrode’s buffer was added, 
carefully mixed into the blood without inverting the tube, and more PRP removed after a 
second, identical, spin. A third spin at 530 g for 5 min on the pooled PRP pelleted the 
platelets, plasma was removed, and the platelets were re-suspended in Tyrode’s buffer 
at 2 x 108 ml-1. Half the platelets were used as unstimulated controls, and the rest were 
activated with 0.2 U/ml thrombin and 1 mM CaCl2 followed by gentle mixing every 2 - 3 
min for 30 min at 37 °C.  
 
Quantification of blood loss from tail bleeding assays.  C57/BL6 wild type (Charles 
River), 12/15-LOX-/- and p12-LOX-/- mice bred in-house were kept in constant 
temperature cages (20 – 22 °C) and given free access to water and standard chow. Tail 
bleeding assays and breeding of mice was performed under Home Office Licence 
PPL/3150. Male mice (11 week old) were anesthetized using 5 % isoflurane and 
maintained with 2 % isoflurane.  Where administered, liposomes (10 ml generated as 
described above, using either (i) 30 % SAPE, 65 % DSPC, 5 % SAPS, and 2.5 nmol/L 
TF, or (ii) 20 % SAPE, 65 % DSPC, 5 % SAPS, 10 % 12-HETE-PE and 2.5 nmol/L TF) 
were injected immediately proximal of the cut site directly before transection of 2 - 5 mm 
from the distal end and immediate immersion in 37 °C physiological saline. Bleeding 
was observed as blood loss and time to the beginning of stable (1 min) cessation of 
blood flow determined, before killing via cervical dislocation.  Blood loss was quantified 
by measuring the hemoglobin (Hb) content of the saline, as follows. Hemoglobin 
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quantitation was achieved via centrifugation of the tube at 250 x g for 15 min, and 
resuspending the red cells in 5 ml erythrocyte lysis buffer (8.3 g/L NH4Cl, 1 g/L KHCO3 
and 0.037 g/L EDTA in distilled H2O).  The concentration of Hb was measured as 
optical density (OD) 575 nm using a UVIKON 923 double beam UV /VIS 
spectrophotometer (Bio-Tek Kontron Instruments) and expressed as absorbance units 
(AU).   
 
Injury-related venous thrombosis. Thrombosis was induced as described previously with 
minor modifications (5). In brief, mice (20 - 25 g body weight) were anaesthetized with 
ketamin (100 mg/kg body weight) and xylazin (20 mg/kg body weight), and placed under 
a heating lamp to maintain constant body temperature of 37 °C. A ventral midline 
incision was performed and the intestines were gently put aside. The vena cava inferior 
was laid free carefully and a filter paper (1 mm x 2 mm x 4 mm) soaked with 4 % of 
aqueous ferric chloride solution was placed on top of the vessel. After 3 min, the filter 
paper was removed and the peritoneal cavity thoroughly rinsed with pre-warmed 0.9 % 
saline. After another 30 min, mice were sacrificed, blood was taken by cardiac puncture, 
and the vena cava containing the thrombus removed. The clot was dissected free from 
the vessel and prepared under a microscope for further analysis. Wet thrombus weight 
was measured using a precision balance (Sartorius R16P) after removal of excess 
water.  
 
Liposome-β2GPI-HETE-PE binding. Liposomes were prepared by extrusion in Buffer A 
(20 mM HEPES, 100 mM NaCl, pH 7.4), with composition as described earlier (6). 
Liposomes were immobilized onto Polysorp plates (Nunc) coated with 5 µg/ml 
Neutravidin.  1 µg/ml β2GPI was added for 1 hour at room temperature. Bound β2GPI 
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was determined using anti-β2GPI-HRP antibody (1:20,000) (Cedarlane) and ECL 
detection (Pierce).  Data is expressed as the relative light units in 100 ms (RLU/100 
ms).  
 
Lipid Bilayer Model Preparation, and membrane energy minimization and simulation 
protocol.  A pre-equilibrated hydrate lipid bilayer consisting of 128 molecules of 1,2-
Dioleoyl-sn-glycero-3-phosphocholine (DOPC), based on a previously reported study, 
was downloaded from the ATM database (Box ID: 30) (7,8). The lipid bilayer was 
structurally modified by removing DOPC using the MOE (9) builder tools according to 
the experimental composition of the tested liposomes to give the following composition: 
5 % SAPS, 5 % SAPC, 30 % SAPE, 55 % DOPC, 5 % 12-HETE-PC. Initially, a 
conformational analysis of 12-HETE-PC was performed with two different low energy 
conformations included in the membrane. The first presented the oxidized lipid chain in 
an elongated structure and was used for the three 12-HETE-PCs in one monolayer. The 
second presented the oxidized chain in a bent conformation and was used in the other 
monolayer. As a result, the 12-HETE-PC presented the OH group differently on the two 
different membrane layers: on one side the hydroxyl groups were placed deep in the 
membrane, while they were close to the membrane surface on the other side. All the 
modified lateral chains were minimized in MOE using an OPLS-AA force field with a 
gradient of 0.1Kcal/mol/Å2.  Hydrate membrane energy minimization and simulation 
were performed by using Desmond (Maestro interface) with OPLS_2005 set of force 
field parameters (10,11). The TIP3P water model was used and the assembled system 
consisted of 35426 atoms enclosed in a 69 x 70 x 80 Å3 triclinic box. 14 molecules of 
CaCl2 were added as salt. Energy minimization of the system was run with a steepest 
descent until gradient threshold of 25 kcal/mol/Å was reached. A 300 ns MD simulation 
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was then performed using the Desmod default parameters with the temperature set to 
300 K, pressure set at 1.01325 bar and the time step was set to 2 fs. Energy of the 
simulation was recorded every 120 ps, whereas the trajectory was recorded every 480 
ps. 
 
Measurement of calcium binding to membranes. Glass tubes were pre-washed using 1 
M hydrochloric acid and methanol. All buffers were treated using 10 mg/ml pre-washed 
chelex-100 and kept in plasticware to reduce calcium contamination to 1 - 2 µM. 
Liposomes containing 65 % DSPC, 30 % SAPE, 5 % SAPS liposomes, or with SAPE 
replaced with up to 10% 15-HETE-PE were prepared in potassium phosphate buffer. 
Free calcium concentration in the samples was measured using 1 µM Fluo-FF calcium 
dye (Kd 9.7 mM, ex 485 nm, em 520 nm), with 10 or 20 µM calcium added. Decreases 
in free calcium in lipid solutions compared to the buffer blank represents membrane-
bound calcium. A standard curve for Fluo-FF response was constructed using 10 mM 
nitrilotriacetic acid (Kd 78.6 µM) as calcium buffer.  
 
i.e     [Ca2+]membrane   = [Ca2+]total  -  [Ca2+]free - [Ca2+]Fluo-FF bound - [Ca2+]contaminants 
and for the buffer blank: 
     [Ca2+]total   =  [Ca2+]free - [Ca2+]Fluo-FF bound - [Ca2+]contaminants 
 
 
Thrombin-Antithrombin (TAT) complex measurement. Whole blood was collected via a 
cardiac puncture into one-tenth volume of 3.8 % sodium citrate as an anticoagulant and 
centrifuged at 3,000 x g for 10 min.  Plasma thrombin-antithrombin (TAT) levels were 
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determined using a commercially available enzyme-linked immunosorbent assay 
kit (Mouse Thrombin-Antithrombin Complexes ELISA Kit; ab137994, abcam). 
 
Heatmap and Cytoscape correlation.  Heatmaps were generated using the pheatmap 
package in R (version 3.3.1). Data was first normalised to the mean of the unstimulated 
control values for each lipid. Network analysis was performed with Cytoscape (version 
3.4.0), utilizing pairwise correlations between lipids generated with R. The network 
diagram shows only correlations with a Pearson product-moment correlation coefficient 
value (r) > 0.8, due to the high number of interactions. 
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Figure	 S1.	 Primary	 data	 for	 generaEon	 of	 eoxPL	 by	 wild	 type	 and	 p12-LOX-/-	 washed	
platelets.	 	Blood	was	taken	by	cardiac	puncture	and	washed	platelets	isolated	as	in	Methods.		
Platelets	were	acSvated	using	thrombin	as	outlined	in	Methods	then	analyzed	for	eoxPL	using	
LC/MS/MS.	 	Levels	are	expressed	relaSve	to	internal	standard	(DMPE/DMPC)	(n=3,	mean	+/-	
SEM).			
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Figure	 S3.	 Primary	data	 for	 generaEon	of	 eoxPL	by	human	washed	platelets	 from	HC	and	
APS	paEents.	 	Washed	platelets	were	acSvated	using	thrombin	as	outlined	in	Methods	then	
analyzed	 for	 eoxPL	 using	 LC/MS/MS.	 	 Levels	 are	 expressed	 relaSve	 to	 internal	 standard	
(DMPE/DMPC)	(n=16	HC,	n=10	APS,	mean	+/-	SEM).			
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ﬁg.	S4	 CorrelaSon	plot	for	paSent	samples	
CorrelaSon	plot	for	healthy	control	samples	
Figure	 S4.	 CorrelaEon	 plots	 for	 lipids	 from	 either	 HC	 or	 APS	 groups	 shows	 that	 lipids	 group	
according	to	enzymaEc	origin.	 	CorrelaSons	between	lipids	across	the	whole	cohort	were	plo^ed	
in	a	grid,	 in	order	of	decreasing	correlaSon	as	described	 in	Methods.	Red:	p12-LOX,	blue:	COX-1,	
green:	polyoxygenated	PL,	black:	unknown	origin.				
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Figure	S1.	Primary	data	for	generation	of	eoxPL	by	wild	type	and	p12-LOX-/-	washed	
platelets.	 	 Blood	 was	 taken	 by	 cardiac	 puncture	 and	 washed	 platelets	 isolated	 as	 in	Methods.	 	Platelets	were	activated	using	thrombin	as	outlined	 in	Methods	then	analyzed	for	 eoxPL	 using	 LC/MS/MS.	 	 Levels	 are	 expressed	 relative	 to	 internal	 standard	(DMPE/DMPC)	(n=3,	mean	+/-	SEM).		 
Figure	S2.	Analysis	of	HC	and	APS	demographics	for	effects	on	eoxPL	generation	shows	
no	 effect	 of	 age,	 gender	 or	 arterial	 thrombosis	 on	 platelet	 12-HETE-PEs.	 	 Data	 was	analysed	for	platelet	12-HETE-PEs,	either	unstimulated	(US)	or	following	thrombin	treatment,	versus	(A)	age,	APS,	(B)	age,	HC,	(C,	D)	gender,	(E)	venous	vs	arterial	thrombosis.		 
Figure	S3.	Primary	data	for	generation	of	eoxPL	by	human	washed	platelets	from	HC	
and	 APS	 patients.	 	 Washed	 platelets	 were	 activated	 using	 thrombin	 as	 outlined	 in	Methods	 then	 analyzed	 for	 eoxPL	 using	 LC/MS/MS.	 	 Levels	 are	 expressed	 relative	 to	internal	standard	(DMPE/DMPC)	(n=16	HC,	n=10	APS,	mean	+/-	SEM).		 
Figure	S4.	 Correlation	plots	 for	 lipids	 from	either	HC	or	APS	groups	shows	 that	 lipids	
group	according	 to	enzymatic	origin.	 	Correlations	between	lipids	across	the	whole	cohort	were	plotted	in	a	grid,	in	order	of	decreasing	correlation	as	described	 in	Methods.	Red:	p12-LOX,	blue:	COX-1,	green:	polyoxygenated	PL,	black:	unknown	origin.			 
